Elacestrant
- Generic Name
- Elacestrant
- Brand Names
- Orserdu
- Drug Type
- Small Molecule
- Chemical Formula
- C30H38N2O2
- CAS Number
- 722533-56-4
- Unique Ingredient Identifier
- FM6A2627A8
- Background
Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its abili...
- Indication
Elacestrant is indicated for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 18
- Registration Number
- NCT06691035
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT06638307
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- SciClone Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT06544577
- Locations
- 🇨🇳
Hainan Hospital of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (Boao Research Hospital, Hainan), Qionghai, Hainan, China
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 4220
- Registration Number
- NCT06492616
- Locations
- 🇺🇸
Cancer Centers of Kansas, Wichita, Kansas, United States
🇺🇸Miami Valley Hospital South, Centerville, Ohio, United States
🇺🇸Virginia Cancer Institute, Mechanicsville, Virginia, United States
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 240
- Registration Number
- NCT06382948
- Locations
- 🇪🇸
Hospital Universitario Doce de Octubre, Madrid, Spain
🇪🇸Hospital Arnau de Vilanova de Valencia, Valencia, Spain
🇬🇧Barts Health NHS Trust, London, United Kingdom
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 400
- Registration Number
- NCT06075953
- Locations
- 🇺🇸
Berkeley Outpatient Center, Berkeley, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 48
- Registration Number
- NCT05982093
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸Complejo Hospitalario San Pedro de Alcántara, Cáceres, Spain
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05618613
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Phoenix, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Cancer Treatment Centers of America - Midwestern Regional Center, Zion, Illinois, United States
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05596409
- Locations
- 🇲🇽
Fucam, Ac., Ciudad de Mexico, Mexico
🇺🇸Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇺🇸OPN Healthcare, Arcadia, California, United States
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05563220
- Locations
- 🇩🇪
Universitaetsklinikum Mannheim, Mannheim, Baden-Wuerttemberg, Germany
🇺🇸Dothan Hematology and Oncology, Dothan, Alabama, United States
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.